Yes, MHC Class I molecules can serve as biomarkers for both the prognosis of cancer and the effectiveness of certain treatments. For instance, tumors with high MHC Class I expression are generally more susceptible to immune-based therapies. Conversely, low expression can indicate a need for alternative therapeutic strategies.
